$150 billion. That’s how much some experts estimate weight-loss drugs could bring in in sales within the next five years.
Motley Fool analyst Karl Thiel joins Ricky Mulvey to check in on the GLP-1 landscape. They also discuss:
- How weight-loss drugs actually work, and how big-name prescriptions differ from each other.
- What investors need to know about Ozempic and Mounjarno’s patent cliffs.
- The scenarios in which Novo Nordisk and Eli Lilly are actually undervalued.
Companies discussed: LLY, NOVO, HIMS, PFE, RHHBY, VKTX, GPCR, ISRG
Host: Ricky Mulvey
Guest: Karl Thiel
Producer: Mary Long
Engineer: Rick Engdahl
Learn more about your ad choices. Visit megaphone.fm/adchoices
